Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Selzentry

Phase 2Small molecule

IIcahn School of Medicine at Mount Sinai

Selzentry is one of 12 small molecule programs targeting Long COVID-19. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

Long COVID-19Recruiting

Long COVID-19Phase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Long COVID-19

#DrugCompanyPhaseTrials

Revia

Epidiolex

Jazz Pharmaceuticals

Norvir

Corlanor

Celebrex

PPhiladelphia Eye Associates

Valtrex

GGlaxo Dba Glaxosmithkline

Lithobid

SSolvay Pharmaceuticals

Trental

VValidus Pharmaceuticals

Rapamune

PPrism Pharmaceuticals

N-803

IImmunityBio, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Long COVID-19

NCT06511063

Clinical

Trials by Indication[1]

Long COVID-191 trial

Antiviral Clinical Trial for Long Covid-19

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06511063·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Selzentry. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selzentry compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selzentry. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Icahn School of Medicine at Mount Sinai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIcahn School of Medicine at Mount Sinai

Related News